ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up

IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC

Clinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL

CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor

Highlights from ASCO 2021

OncoAlert and ecancer ASCO roundup - Day 3

OncoAlert and ecancer ASCO roundup - Day 2

OncoAlert and ecancer ASCO roundup - Day 1

Incidence and trends of HPV-related cancers in the United States

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma